Dr. Bruce Lavin is Vice President and Head of Medical Affairs, Neurology Patient Value Unit and Head of External Engagement and Policy. He is also an actively practicing physician in Internal Medicine, Infectious Diseases, and Critical Care.

Dr. Lavin has more than 30 years of Clinical experience including over 20 years of Pharmaceutical Industry experience. He has lead Medical Affairs and Clinical Development Divisions and Therapeutic Divisions where he held senior medical executive roles for Bristol Myers-Squibb, Novartis and Sanofi-Aventis in the areas of Infectious Disease, Immunology, Transplantation, Virology and Neurology. Dr. Lavin previously served as Head of Clinical Medicine in the Northern California VA system and US Navy.

Dr. Lavin holds a Bachelor’s degree from the University of California Irvine and a Master’s Degree of Public Health from the University of California, Los Angeles. He received his Medical Degree from the F. Herbert School of Medicine in Maryland. He is Board Certified in Internal Medicine and Infectious Diseases and has certifications in Aerospace Medicine and Health Law.

Dr. Rowe has well over a decade of research experience spanning from pre-clinical to late phase drug development programs, primarily in respiratory (and cardiovascular) medicine.He has been directly responsible for medical strategy and lifecycle management of several Chronic Obstructive Pulmonary Disease (COPD), asthma,thrombosis, and cardiovascular medicines. Dr. Rowe has been successfully involved in achieving New Drug Application (NDA) approvals for first in therapeutic class respiratory products and also has led various clinical development global projects from phase II through phase IV clinical trials.            

He has authored and co-authored several publications in respiratory medicine (COPD-focused, and is a frequent lecturer and speaker at professional society meetings, and educational forums.Dr. Rowe holds degrees from Harvard University and the University of Rochester School of Medicine, and certifications from the London School of Economics and Villanova University.

Dr. Rowe is an active member of several national and international societies and he recently served as Vice Chair of the Drug, Device, Discovery, and Development Committee of the American Thoracic Society (ATS)and has received the distinction of being named a ATS Fellow.               He has a primary interest in promoting international medical research collaboration and innovation across government, academia, and industry.

In his current role, Dr. Rowe is responsible for building and leading a Global Medical Affairs team and strategy within the respiratory space for several novel compounds in mid and late stage development, in various therapeutic indications.

Andres Stern is the Region Europe Medical Excellence and MSL Director in Novartis Oncology. He has 14 years’ experience in the pharmaceutical industry in different roles such as Medical Advisor, MSL Manager and Therapeutical Area Head. Prior joining Novartis he served in Wyeth in Rheumatology and in Grunenthal Pharma dedicated to Pain.

Andres was born in Buenos Aires, Argentina in 1976 and lives in Spain since 2005. Since 2017, he joined the Region Europe HQ in Milan. He holds a medical degree from maimonides university, Argentina.

In his current position in the world wide team, Andres leads and coordinates a team of over 450 Medical Affairs associates across Europe and his focus areas are Solid Tumors and Onco Hematology and ensures that the medical affairs organization in Europe is equipped with the needed capabilities towards the future both for the field and non-field roles.

Liz Clark is a pharmaceutical physician with over 25 years’ experience in the Pharmaceutical Industry.  Having qualified in Medicine at Imperial College London, she undertook 4 years of general medicine prior to joining pharma.  She has held both office and field based roles in Medical Affairs, Marketing and Sales Management, working with both medicinal products and devices.  She is currently Vice President of Medical Affairs at Norgine Ltd. where she is responsible for leading Norgine’s patient engagement work.  In her spare time Liz enjoys gardening, running and yoga.

Dr. Annlouise Assaf is a pharmacoepidemiologist who is Senior Director and Enterprise Benefit Risk Medical Director in the Global Medical Impact Assessment group at Pfizer.  In this role, she partners to evolve the science and practice of Benefit Risk to inform better outcomes for patients, drug development, and healthcare decisions. A focus of her work is on quality benefit risk communication and improving health literacy and patient-centered medication prescribing so that patients can make informed shared decisions about their treatment, use their medications safely and appropriately, and improve value outcomes. Dr. Assaf is also a co-lead on the Health Literacy Working Group at Pfizer. Dr. Assaf joined Pfizer in 2002 after many years in academic medicine and clinical research at Brown Medical School.  She received her doctorate from the Roswell Park Cancer Institute in Buffalo where she
focused her research efforts in the field of cancer and cardiovascular disease epidemiology with a particular focus on diseases which disproportionately affect women and patients with low health literacy.   

Dr. Assaf was Co-Principal Investigator of the Pawtucket Heart Health Program, a community-based intervention for prevention of cardiovascular disease, where she specialized in the evaluation of programs aimed at behavior change in low health literacy, low income, and minority populations.  Dr. Assaf has been Principal or Co-Principal Investigator for numerous NIH clinical trials.  She was a Principal
Investigator and Executive Committee Member of the Women’s Health Initiative (WHI) Clinical Trial and Observational study and ran the largest of the 40 clinical centers of WHI. She has served in numerous teaching, consulting, and leadership roles nationally and internationally and is currently a Professor (Adjunct) at The Brown University School of Public Health. She has published over 100 scientific articles, book chapters, and abstracts.

Medical doctor, 25 years of experience at various levels of management at the pharmaceutical industry. General Management, Medical Affairs, Sales, Marketing, Business Development, , Regulatory, Compliance, and R&D. Last 10 years: OPDF President Board of Directors, one of the biggest Polish pharmaceutical group, Associate Medical Director at Sanofi Genzyme (Rare Diseases, MS, Oncology, Immunology), CEE Medical Launch Lead at Merck Group.  

Now: Neurology&Immunology EMEA Medical Director at Merck Group.

Author and co-author scientific medical and pharma law publications. Guest lecturer at the Warsaw University.

Awards examples: 2007 and 2008 the "Client's Golden Laurel" for the best Polish pharmacy network. “The Master of 2009” for outstanding contribution for a development of the Polish pharmacy wholesale market. "Reliable Employer 2009"

In private life is interested in psychology of the society and cognitive, prose, social and politic changes, world history as well as travelling, sailing, windsurfing and skiing, books reading. Loves to spend time with family.

Dr. Ruth Duffy joined Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) in 2013.  Dr. Duffy is currently Senior Medical Director and head of US Medical Affairs, Neuroscience, for OPDC.  She leads a team in the development and implementation of medical strategy, including publication planning, grant and IST approval, and new data generation for marketed neuropsychiatric products within the U.S. In addition, her team supports all field, sales and speaker training, and has responsibility for medical review of all US promotional materials for the Neuroscience commercial organization. 

Prior to joining Otsuka, Dr. Duffy had a long career in preclinical drug development and translational medicine at Schering-Plough and later at Merck, where she was a Director of In Vitro Pharmacology. 

Dr. Duffy received her B.A. degree from Chatham College and her Ph.D. in Neuroscience from the City University of New York.   She is currently a member of the New York Academy of Sciences, the American Society of Clinical Psychopharmacology (ASCP) and the Medical Affairs Professional Society.

Distinguished and accomplished Pharma Medical Affairs professional with diverse global, regional, and in-country experience over two decades, in launching interventions in various therapy areas, including biologics and small molecules. Proven expertise in leadership roles. Respected speaker and author on Medical Affairs function.

Fernando is the Oncology MSL Manager of Janssen UK. In his role, he is responsible for providing leadership, coaching, guidance and development of his MSL team and the overall UK MSL function. He is also a member of the strategic, cross-functional oncology leadership team in the UK. Previous to this role, Fernando was the Janssen Europe Middle East and Africa (EMEA) Medical Affairs Strategic Projects Manager, where he drove a cross-functional team to successfully develop and implement an ambitious strategic programme to upskill and develop Janssen’s 400+ MSLs and MSL Managers workforce across EMEA.

Fernando has a BSc + MSc in Biotechnology from Salamanca University (Spain) and Melbourne University (Australia) and a MRes in Genetic Medicine from the University of Manchester. He has worked in cancer research in academia in Spain and in the Breakthrough Breast Cancer Group at Cancer Research UK. He also worked in AstraZeneca in R&D as a research scientist in the Oncology Pre-Clinical Development and Oncology Precise Medicine teams. Before joining Janssen, he was awarded a full merit scholarship to study Management at London Business School.

Addicted to Digital Transformation with 30 years of experience in Biology, Genomics, Market Intelligence, IT-Portfolio-, Product-, Program-, Project- and  Line-Management.

Ulf got his PhD in microbiology and genomics at the Max-Planck-Institute for terrestrial Microbiology Marburg. After postdoc awardee his business stations were the Georg Thieme Verlag, Stuttgart and the Bertelsmann AG (Lycos Europe GmbH) before he joined Bayer in 2002. From 2015 he has been Digital Innovation Manager, supporting Bayer’s path in Digital Transformation, since 2019 he is Business Partner for Medical Affairs and Pharmacovigilance. Current projects are Proof of Concept in quantum computing and the implementation of a non-interventional study for the mobile detection of atrial fibrillation. He enjoys mountain- and racing-biking, soccer and guitar playing.

……..Innovation is just a thought away………

Ghiesla Nel, B Pharm, is Head of Global Medical Information at Ipsen. Ghiesla started her Pharma career at GSK in 2005 and since has gained a broad experience in both Medical Information and Pharmacovigilance in small, medium and large Pharma. Ghiesla has experience in setting up local (and now global) Medical Information functions, sourcing and implementing a global medical information database as well as successfully outsourcing first line medical information services.  In the middle of her Medical Affairs career Ghiesla did a 4-year tenure in marketing which harnessed her strategic thinking and brought unique perspectives on the value of Medical Information.

AJ qualified as an MD at the Free University of Amsterdam (NL) and worked several years in Internal Medicine in Amsterdam. In 2008 he joined Roche in Basel from Schering-Plough/Organon in New Jersey
to take over the leadership of the Ocrelizumab Multiple Sclerosis
Life Cycle team. In February 2013 he was appointed Therapeutic
Area Head Medical Affairs Neuroscience/Cardio-Metabolism and
in October 2015 he took the opportunity to build and lead the Medical Affairs Team at Roche Diagnostics in Rotkreuz. He started his career in Pharma as a Medical Advisor CNS with Solvay Pharma in the Netherlands working in Depressive and Anxiety Disorders. After several years of operational work at the affiliate level he joined Solvay
Pharma International as Medical Manager Middle East and Asia Pacific. In 1998 he joined Organon International where he predominantly worked in Neuroscience (depression, bipolar disorders, schizophrenia) and developed experience across the value chain being involved in Strategy Development from Proof of Concept to the implementation of Medical Strategy at affiliate level. In 2002 he joined the US Headquarters where he was Executive Director Neuroscience, both as Global Marketing Director and Global Medical Affairs Lead.

With a background in academic clinical medicine Nermeen is an experienced business leader who has founded, grown and exited from global life sciences businesses in start-up and corporate settings. She is a recognised expert and thought leader in the clinical development of pharmaceuticals and medical devices. With a strong interest in innovative and pragmatic approaches for the generation of clinical evidence to enable adoption of new treatments, Nermeen is developing BTG’s approach for utilising big data technologies including AI and Real World Evidence for the assessment of clinical outcomes.

Dr Varawalla completed her undergraduate and specialist medical training at the University of Mumbai, before receiving a Rhodes Fellowship to the University Oxford where she obtained her doctorate from the Institute of Molecular Medicine. She is a Fellow of the Indian College of Physicians & Surgeons and a Member of the Royal College of Obstetrics and Gynaecology.

As a SYLFF fellow, Nermeen completed an MBA at INSEAD, following which she worked at Accenture’s Strategy Consulting Practice. Since then she has worked in the clinical development industry with contract research organisations, pharmaceutical and medical device companies. She serves as a Trustee of the Malaria Consortium.

Kevin Appareti is Senior Director, Global Medical Science Liaison in the Chief Medical Office at Royal Philips.  He leads the Key Thought Leadership Program and works across Philips’ businesses, markets, and research to build strong internal and external relationships with key thought leaders and influencers.  Kevin partners with internal business, market, and research leaders to develop strategic Key Thought Leader (KTL) engagement programs to deliver strategic guidance, leverage clinical and scientific knowledge, foster peer-to-peer relationships, and support clinical and marketing evidence development in support of Philips meaningful innovations.

Prior to the 7 years he has been in the Chief Medical Office, he had 25 years of experience in the Ultrasound Business Unit where he held a variety of leadership positions. He was senior marketing manager of the global luminary program where he contributed to establishing a structured approach to thought leader management. He was also worldwide market development manager and director of product marketing for cardiovascular ultrasound where he brought to market many cardiovascular ultrasound products that set the standard in performance and reliability.  He has held additional positions in marketing management for profes­sional services, information technologies and clinical marketing.

He began his academic, research and clinical career as Program Director for Diagnostic Medical Ultrasound Education at the University of Colorado Health Sciences Center where he was involved in clinical research in fetal echocardiography, neonatal brain imaging, and ultrasound technology assessment.  He has co-authored many scientific papers, book chapters and presented at numerous international scientific conferences.

He then moved to industry with various clinical and management roles with Hewlett Packard, Agilent Technologies, and now Royal Philips.  Kevin holds a bachelor’s degree in physical science from Colo­rado State University and an MBA from Boston University and has been an adjunct professor at the University of Massachusetts at Lowell, Manning School of Business.

Kevin is married and has 4 boys.  He enjoys basketball, road cycling, tennis and he is an avid photographer.

Tobias M Suiter, MD is an expert in Global Biologics Industry (rare disease) and has more than 20 years of senior industry experience. He holds his expertise in global and regional medical affairs leadership, product and franchise launch strategies/tactics, implementation of global and regional medical affairs departments, life cycle management, rare disease management, recombinant & transgenic therapeutic proteins, plasmaprotein therapeutics, pharmacovigiliance & virology. He is currently acting as Vice President Medical Affairs (Pharming NV, NL) implementing medical affairs country organizations and re-launch strategy/tactics. Prior to this assignment, he worked as Vice President Global Medical Affairs (Biogen, US) and Head of Global Medical Affairs as well as Global Head of Commercial Development Coagulation Portfolio (CSL Behring, D).

Ondrej Novak studied medicine in Prague, Czech Republic and Homburg/Saar, Germany, and management at Cranfield University in the UK. Of his overall 17 years in the pharma industry he spent the last 9 working in international medical affairs, specializing in introducing innovative drugs into new territories. Ondrej worked for small firms and start-ups such as EUSA Pharma, Intermune or Aegerion. He currently works as Medical Director at Kyowa Kirin, leading medical affairs in the region of Central and Eastern Europe, Middle East, Russia, Israel and Turkey. Over the past 9 years rare diseases and orphan drugs have been Ondrej’s main scientific interest, with a special focus on areas such as pediatric oncology, pneumology, or lipid and bone metabolism disorders.

Elizabeth is a registered and licensed dietitian with 20 years of clinical nutrition experience.  She leads the Medical Affairs Division for Gelesis, with focus and interest in Obesity, Nonalcoholic Liver Disease, and Nonalcoholic steatohepatitis. Before joining Gelesis, she was Head of Medical Science for Abbott Nutrition. Prior to that, she served as Senior Director of Medical Affairs at Medtronic/Covidien from 2011-2016.  Elizabeth has tremendous clinical nutrition experience as previous Head of the Department of Nutrition Therapy, at The Cleveland Clinic 2003-2011. While there, she focused on critical care, artificial nutrition support, and served as a medical media representative, providing commentary and discussion on late breaking trials and research within the field. Elizabeth remains guest faculty at Cleveland Clinic, actively involved with their advanced practice residency program.
She has been appointed and elected to many committees and leadership positions by the American Society of Parenteral and Enteral Nutrition, The Society of Critical Care Medicine, and The Academy of Nutrition and Dietetics’ Dietitians in Nutrition Support, where she currently serves as a House of Delegates Officer.  Elizabeth has lectured throughout the U.S. and internationally on malnutrition, clinical nutrition support, related critical care and surgery topics, as well as medical affairs. She received a Master of Science in Nutrition, with focus on Pathophysiology from the University of Akron and a Bachelor of Science in Food and Nutrition from Youngstown State University. Elizabeth is currently pursuing her PhD in Health Science at Nova Southeastern University.

Peter Shaw is Global Vice President of Medical Affairs and Chief Medical Officer at Bioventus having spent the previous three years as Senior Medical Director in Medical Affairs at Ferring Pharmaceuticals where he was responsible for all US Orthopaedic and Specialty Products. Prior to that Peter was Chief Medical Officer at Emisphere Technologies and Q-Pharma. He received his medical training at the University of London, Charing Cross & Westminster Hospital Medical School and postgraduate medical education in Orthopaedics and General Surgery as well as OBGYN, General Medicine, Cardiology and Cardiopulmonary Transplant Medicine. He practiced in the United Kingdom for 23 years before entering the pharmaceutical industry and moving to the USA in 2006. While in clinical practice, Peter was also post-graduate tutor in primary care and attending physician to a professional rugby club for 13 years.

Dr. Costigliola graduated in Medicine from the University of Naples in 1972 and in Anaesthesiology and Intensive Care from the University of Pisa in 1978. He also attended post-graduated studies in Rheumatology, Dermatology, Proctology, Oncology, Surgery, Drugs Abuse, Emergency Treatment, Disaster Action, Hospital Organization, Medical Teaching Methodology and Computer and Audio-Visual Training for the Medical Profession. His professional experience ranges from senior military positions as Chief of Medical Services in the Italian Navy for a number of years, responsibility of the outpatients clinic of the Shape Hospital in Belgium and family practice in Italy and Belgium. Dr. Costigliola practice in Italian, French, English and Spanish.

Alex Wyke is CEO and founder of PatientView, a UK-based research, publishing and consultancy group. PatientView has worked to build bridges worldwide with the health NGOs that comprise the patient movement, to help define and support one of the most important phenomenon changing healthcare in the 21st Century. (For more on PatientView, see: www.patient-view.com). PatientView is the publisher and owner of the series Corporate Reputation of Pharma – from a patient perspective, Benchmarking the patient Movement as well as the online mhealth resource for public and patients, myhealthapps.net.

From 1996 to 2000 Alex was responsible for creating and running the international healthcare publishing unit at The Economist Intelligence Unit. She was previously business and science correspondent for The Economist.

Isabelle Hilali is CRI - Center for Research & Interdisciplinarity’s Managing Director. CRI is a unique place that experiments and spreads new ways of learning, teaching, conducting research and mobilizing collective intelligence in life, learning and digital sciences. She is also Board Member of the Healthcare Data Institute, a think tank, that gathers
a large community of big data and health experts. As a true and positive leader, she is a dedicated professional committed to the health and education fields. Before joining CRI, Isabelle held several senior management positions in the eHealth field as well as in the mobile and internet industry, both in France and internationally. She holds a Masters
degree from “Institut d’Etudes Politiques (Sciences Po) de Grenoble” and “Université Paris I - Panthéon Sorbonne” in Military Strategy.

With more than 18 years diversified experience in the life sciences vertical, Peter has been involved in digital pharmaceutical communications since 1996. His leadership in strategic planning, revenue generation, and business partnering has established a strong and diverse client-base for Within3. His expertise and experience in working closely with organizations to adopt new technologies proves invaluable to clients and partners as they adopt new solutions. His consultative demeanor and willingness to work collaboratively continually provides benefits to clients and partners old and new as Within3’s business grows and evolves.

As part of the leadership team for Hyphen, an Omnicom-owned digital agency, Peter developed and implemented strategies that established Hyphen’s market presence, grew product offerings, and drove business development and customer acquisition. Hyphen grew exponentially from 2003 to ­2007, quadrupling staff and revenues while acquiring new clients and opportunities annually. Peter has also held positions with Sermo, Peer Direct, Torre Lazur, and Commonhealth developing business and leading accounts. Peter has worked extensively across the industry resulting in successful innovation for clients and healthcare professionals alike.

Richard’s early career was as a Senior Consultant for a major multi-national business consultancy. This enabled him to observe and experience first-hand workplace issues such as management culture, stress and conflict.

His core areas of expertise include Emotional Intelligence and Resilience. Richard coaches C-Suite leaders on themes such as Charisma and Conscious Leadership, as well as helping management teams to work more effectively towards common goals and objectives.

As a practicing coach and qualified psychologist, he has advised organisations such as Google, PwC, KPMG, Ernst & Young, Cap Gemini and Reckitt Benckiser.

Richard is also recognised by the media where he is often asked for expert commentary, having appeared on Sky 1, BBC, Bloomberg, and Radio 5Live.

Gemma is an Executive with Vynamic, a Healthcare Industry Management Consulting company that approaches healthcare as five interwoven sectors. Gemma has more than 20 years of Healthcare experience, with a major focus on Global Medical Affairs. Her interests are in partnering with clients to design and implement strategic frameworks, business processes, and operating models that complement the evolving priorities of pharma and biotech organizations.

Tessa graduated with a degree and professional diploma in Strategic Marketing in the early 1990s. Her formative years were spent in client facing roles at advertising agencies, including Saatchi and Saatchi and FCB in London, where she looked after Financial Services and FMCG clients. Tessa launched PharmaReview 7 years ago, with Dr Ralph Carter.  PharmaReview is a   specialist provider of outsourced copy review services to the pharmaceutical industry.  Its  mission is to reduce the time and cost which internal copy review places on senior members of  clients’ medical, regulatory and commercial teams while maintaining the highest levels  of regulatory adherence and compliance. Tessa is a highly experienced practitioner in ZincMAPS and Veeva Vault PromotMats functionaility and a copy review process expert.

Angela Rylands heads up the OPEN VIE Patient Centred Outcomes (PCO) research group. As a Principal Consultant of the PCO research team, Angela oversees the design, development and implementation of all PCO projects. Angela has worked both within and directly with top global pharmaceutical clients for past 10 years. Previously Angela worked as the lead Patient-Centred Outcomes Scientist for global trial teams at Roche, and prior to this Angela consulted pharmaceutical companies for a specialist contract research organisation. Angela trained as a Research Psychologist at academic research centres of excellence (Oxford University) and their related NHS healthcare sites. Dr Rylands has extensive experience overseeing both quantitative and qualitative research projects, in providing training, as well as running interviews with clinical and non-clinical populations. Angela is a registered Chartered Psychologist, with a post-graduate doctor of philosophy degree in Psychology and Neuroscience from the University of Manchester and an undergraduate BSc degree in Psychology from the University College of London. 

Timo is a senior member of Syneos Health’s Scientific and Medical Affairs Advisory Group – leading its efforts across Europe. Timo advises clients in organization and product strategy as well as launch and lifecycle management topics – primarily in Medical Affairs but with a strong cross-functional perspective. Across all his project work, the primary theme is how to increase the value Medical Affairs organizations are delivering to external stakeholders (opinion leaders, practitioners and patients) and internal teams. Prior to joining Syneos Health, Timo worked at leading strategy consulting firms (incl. the Monitor Group and Roland Berger Strategy Consultants) advising pharmaceutical and MedTech clients across Europe and the US.

Alexandra Zemp is Partner with McKinsey. She is co-leading McKinsey’s Medical Affairs practice in Europe with a specific focus on capability building. Beyond that, her Medical Affairs work spans from designing Medical Affairs organizations, over defining Medical Affairs strategies, to defining & implementing digital innovation in Medical Affairs, such as advanced analytics on real world data.

Erwin De Cock, MSc is a health economist and real-world data scientist with over 18 years of biopharmaceutical consultancy experience. Erwin joined Syneos Health early 2017. Prior to this, he held various roles at United BioSource Corporation, a CRO specialized in late stage research, where he was responsible for the design of observational studies and having managerial and business development responsibilities. Erwin is an industry expert in observational Time and Motion studies, retrospective chart review studies, and has expertise in other real-world late phase studies using retrospective and prospective designs. He has a strong pharmacoeconomics background including economic modelling and the generation of value messages. This experience is instrumental in conceptualizing late phase studies that aim to generate economic and patient-centered value messages. He has a solid publication track record in the areas of late stage research and health economics and has presented at numerous meetings and conferences. Erwin obtained his Master’s Degree in Applied Economics (specialization in International Business) from the Katholieke Universiteit Leuven, Belgium, and a Diploma in Health Planning and Management from Birkbeck College, University of London.

Ian is an experienced Medical Affairs professional with a demonstrated history of working in the pharmaceutical industry and medical communications agencies. He has strong skills in medical education, medical communications, oncology, drug development and strategic medical planning. He has over 26 years’ experience working in AstraZeneca across a number of functions Including R&D, Operations, Marketing  and Medical. Ian worked in the Global Oncology Medical Affairs franchise for 10 years where he developed strategic medical plans for a number of oncology products and translated them into effective multinational programs to support communications by worldwide affiliate companies. In 2013 he started his own business, Greenway Medcomms Ltd. where he led Medical Excellence training programmes and delivered medical communications and strategic planning projects for pharmaceutical companies. Ian is now Medical Affairs Director at CHV where he provides high-level scientific, strategic and marketing insight combined with scientific leadership of account teams promoting excellence in client service, best practice and operational effectiveness.

Experienced Global Head with a demonstrated history of working in the health and wellness industry. Skilled across many therapy areas, in strategic communication planning, Pharmaceutical Industry, Healthcare, and Medical Communications. Strong business development professional with a MSc focused in Pharmacology & Biological Computation from University of York.